{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:07:51Z","timestamp":1790899671104,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007807","name":"Japan Science Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejpb.2025.114661","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T12:12:03Z","timestamp":1738671123000},"page":"114661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Efficient nose-to-brain delivery of nine residues peptide (JAL-TA9) exhibiting hydrolytic activity against amyloid-\u03b2"],"prefix":"10.1016","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1703-6080","authenticated-orcid":false,"given":"Yusuke","family":"Hatakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4397-4353","authenticated-orcid":false,"given":"Tomoyuki","family":"Furubayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemasa","family":"Katsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomi","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-0623","authenticated-orcid":false,"given":"Toshiyasu","family":"Sakane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2025.114661_b0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13195-017-0297-z","article-title":"Alzheimer\u2019s disease prevention: from risk factors to early intervention","volume":"9","author":"Crous-Bou","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ejpb.2025.114661_b0010","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006148","article-title":"The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment","volume":"2","author":"Tarawneh","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"2020","key":"10.1016\/j.ejpb.2025.114661_b0015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care, report of the lancet commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2025.114661_b0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade","volume":"9","author":"Jr","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejpb.2025.114661_b0025","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","article-title":"Amyloid \u03b2 oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis","volume":"129","author":"Viola","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejpb.2025.114661_b0030","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","article-title":"Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ejpb.2025.114661_b0035","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2025.114661_b0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2025.114661_b0045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.peptides.2019.03.005","article-title":"The discovery of shorter synthetic proteolytic peptides derived from Tob1 protein","volume":"116","author":"Nakamura","year":"2019","journal-title":"Peptides"},{"key":"10.1016\/j.ejpb.2025.114661_b0050","first-page":"30","article-title":"The novel catalytic peptide, A Synthetic Nona-Peptide (JAL-TA9) Derived from Tob1 protein, digests the amyloid-\u03b2 peptide","volume":"1","author":"Nakamura","year":"2019","journal-title":"J. r., Sci."},{"key":"10.1016\/j.ejpb.2025.114661_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2019.e02454","article-title":"Catalytides derived from the Box A region in the ANA\/BTG3 protein cleave amyloid-\u03b2 fragment peptide","volume":"5","author":"Hatakawa","year":"2019","journal-title":"Heliyon"},{"key":"10.1016\/j.ejpb.2025.114661_b0060","article-title":"Amyloid beta cleavage by ANA\u2010TA9, a synthetic peptide from the ANA\/BTG3 Box A region","volume":"7","author":"Hatakawa","year":"2021","journal-title":"Alzheimers Dement. (n y)"},{"key":"10.1016\/j.ejpb.2025.114661_b0065","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3390\/pharmaceutics14061117","article-title":"Therapeutic approach to Alzheimer\u2019s disease: current treatments and new perspectives","volume":"14","author":"Pardo-Moreno","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114661_b0070","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrd.2015.21","article-title":"From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery","volume":"15","author":"Banks","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2025.114661_b0075","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/RMR.0b013e3180332e79","article-title":"Targeted drug delivery to the brain using focused ultrasound","volume":"17","author":"Kinoshita","year":"2006","journal-title":"TOP Magn. Reson. Imaging"},{"key":"10.1016\/j.ejpb.2025.114661_b0080","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood-brain barrier: structure, regulation, and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ejpb.2025.114661_b0085","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.3390\/molecules14093754","article-title":"Nasal delivery of high molecular weight drugs","volume":"14","author":"Ozsoy","year":"2009","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2025.114661_b0090","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.2174\/1381612827666210820100723","article-title":"A recent update on intranasal delivery of high molecular weight proteins, peptides, and hormones","volume":"27","author":"Sharma","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejpb.2025.114661_b0095","article-title":"The nose has it: opportunities and challenges for intranasal drug administration for neurologic conditions including seizure clusters","volume":"21","author":"Chung","year":"2023","journal-title":"Epilepsy Behav. Rep."},{"key":"10.1016\/j.ejpb.2025.114661_b0100","article-title":"On a highway to the brain: a review on nose-to-brain drug delivery using nanoparticles","volume":"29","author":"Formica","year":"2022","journal-title":"Appl. Mater. Today"},{"key":"10.1016\/j.ejpb.2025.114661_b0105","first-page":"439","article-title":"Non-invasive strategies for nose-to-brain drug delivery","volume":"10","author":"Trevino","year":"2020","journal-title":"J. Clin. Trials."},{"key":"10.1016\/j.ejpb.2025.114661_b0110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40005-022-00589-5","article-title":"Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors","volume":"53","author":"Jeong","year":"2023","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.ejpb.2025.114661_b0115","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.3390\/pharmaceutics14091870","article-title":"nose-to-brain delivery of therapeutic peptides as nasal aerosols","volume":"14","author":"Alabsi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114661_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122372","article-title":"nose-to-brain delivery of octreotide acetate in situ gel for pituitary adenoma: Pharmacological and in vitro cytotoxicity studies","volume":"629","author":"Gadhave","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114661_b0125","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3390\/pharmaceutics14061136","article-title":"Gene targeting to the cerebral cortex following intranasal administration of polyplexes","volume":"14","author":"Petkova","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114661_b0130","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jconrel.2021.12.034","article-title":"Enhanced nose-to-brain delivery of siRNA using hyaluronan-enveloped nanomicelles for glioma therapy","volume":"342","author":"Yang","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2025.114661_b0135","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.3390\/cells11193095","article-title":"Nose-to-brain: the next step for stem cell and biomaterial therapy in neurological disorders","volume":"11","author":"Villar-G\u00f3mez","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejpb.2025.114661_b0140","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejcb.2009.02.001","article-title":"Intranasal delivery of cells to the brain","volume":"88","author":"Danielyan","year":"2009","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.ejpb.2025.114661_b0145","first-page":"763","article-title":"Nanostructured lipid carriers for nose to brain delivery targeting CNS: diversified role of liquid lipids for synergistic action","volume":"12","author":"Tekade","year":"2022","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2025.114661_b0150","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/pharmaceutics11020084","article-title":"Nanoemulsions for \u201cnose-to-brain\u201d drug delivery","volume":"11","author":"Bonferoni","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114661_b0155","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3109\/10717544.2013.878857","article-title":"Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization","volume":"22","author":"Shah","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2025.114661_b0160","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","article-title":"Nanoparticles for direct nose-to-brain delivery of drugs","volume":"379","author":"Mistry","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114661_b0165","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s11064-021-03488-7","article-title":"Lipid-based nanocarriers via nose-to-brain pathway for central nervous system disorders","volume":"47","author":"Nguyen","year":"2022","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejpb.2025.114661_b0170","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1208\/s12249-015-0294-0","article-title":"Nose-to-brain delivery of PLGA-diazepam nanoparticles","volume":"16","author":"Sharma","year":"2015","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejpb.2025.114661_b0175","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejpb.2023.06.015","article-title":"Engineered dry powders for the nose-to-brain delivery of transforming growth factor-beta","volume":"189","author":"Wong","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114661_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122038","article-title":"Tailoring functional spray-dried powder platform for efficient donepezil nose-to-brain delivery","volume":"624","author":"Perku\u0161i\u0107","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114661_b0185","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.bmc.2017.11.001","article-title":"Nose-to-brain peptide delivery \u2013 the potential of nanotechnology","volume":"26","author":"Samaridou","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejpb.2025.114661_b0190","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1021\/acs.molpharmaceut.7b00991","article-title":"Delivery of oxytocin to the brain for the treatment of autism spectrum disorder by nasal application","volume":"15","author":"Tanaka","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2025.114661_b0195","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1021\/acs.molpharmaceut.9b00571","article-title":"Transnasal delivery of the peptide agonist specific to neuromedin-U Receptor 2 to the brain for the treatment of obesity","volume":"17","author":"Tanaka","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2025.114661_b0200","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3390\/biom4020510","article-title":"Prion fragment peptides are digested with membrane type matrix metalloproteinases and acquire enzyme resistance through Cu2+-binding","volume":"4","author":"Kojima","year":"2014","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejpb.2025.114661_b0205","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0378-5173(81)90058-2","article-title":"Absorption of drugs from the nasal mucosa of rat","volume":"7","author":"Hirai","year":"1981","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114661_b0210","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0022-3565(25)32758-8","article-title":"Effect of heparin or salicylate infusion on serum protein binding and on concentrations of phenytoin in serum, brain and cerebrospinal fluid of rats","volume":"219","author":"Chou","year":"1981","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejpb.2025.114661_b0215","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jconrel.2021.02.024","article-title":"Quantitative analysis of inulin distribution in the brain focused on nose-to-brain route via olfactory epithelium by reverse esophageal cannulation","volume":"332","author":"Fukuda","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2025.114661_b0220","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ejpb.2025.114661_b0225","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1152\/jappl.1971.30.6.879","article-title":"Measurement of the distribution of cardiac output in unanesthetized rats","volume":"30","author":"Sasaki","year":"1971","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.ejpb.2025.114661_b0230","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijpharm.2015.12.046","article-title":"Nanoparticle transport across in vitro olfactory cell monolayers","volume":"499","author":"Gartziandia","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114661_b0235","first-page":"208","article-title":"Nano formulation: a novel approach for nose to brain drug delivery","volume":"8","author":"Singh","year":"2016","journal-title":"J. Chem. Pharm. Res."},{"key":"10.1016\/j.ejpb.2025.114661_b0240","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3109\/1061186X.2015.1020809","article-title":"Nanotechnology-mediated nose to brain drug delivery for Parkinson\u2019s disease: a mini review","volume":"23","author":"Kulkarni","year":"2015","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2025.114661_b0245","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.2042-7158.1991.tb03510.x","article-title":"Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity","volume":"43","author":"Sakane","year":"1991","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2025.114661_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1341295","article-title":"Research progress in brain-targeted nasal drug delivery","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejpb.2025.114661_b0255","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41398-021-01511-7","article-title":"Nasal oxytocin for the treatment of psychiatric disorders and pain: achieving meaningful brain concentrations","volume":"11","author":"Yeomans","year":"2021","journal-title":"Transl. Psychiatry."},{"key":"10.1016\/j.ejpb.2025.114661_b0260","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1039\/C8CC01400K","article-title":"High-yielding 18F radiosynthesis of a novel oxytocin receptor tracer, a probe for nose-to-brain oxytocin uptake in vivo","volume":"54","author":"Beard","year":"2018","journal-title":"Chem. Commun (Camb)"},{"key":"10.1016\/j.ejpb.2025.114661_b0265","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1172\/JCI67677","article-title":"Brain-wide pathway for waste clearance captured by contrast-enhanced MRI","volume":"123","author":"Iliff","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejpb.2025.114661_b0270","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1007\/s11064-015-1581-6","article-title":"The glymphatic system: a beginner\u2019s guide","volume":"40","author":"Jessen","year":"2015","journal-title":"Neurochem. Res."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125000372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125000372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:39:51Z","timestamp":1762331991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641125000372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":54,"alternative-id":["S0939641125000372"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114661","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficient nose-to-brain delivery of nine residues peptide (JAL-TA9) exhibiting hydrolytic activity against amyloid-\u03b2","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114661"}}